Floatz logo

Pen-866

Solid Carcinoma

Tarveda TherapeuticsPhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

45 Active assets in the Solid Carcinoma cohort.

Asset / SponsorPhaseRating
TIPIRACIL
Academic and Community Cancer Research United
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 1/2B
Trifluridine
Academic and Community Cancer Research United
Phase 2B
Palbociclib
Academic and Community Cancer Research United
Phase 2B
Binimetinib
Academic and Community Cancer Research United
Phase 2B

View all 50 →

Same molecule, other indications

Pen-866 is also rated in:

endometrium adenocarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
anal squamous cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
pancreatic adenocarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →